The current study aims to assess serum SESN2 levels in treatment-naive women with PCOS and compare them to healthy controls, exploring its potential as a stress-responsive protein and a biomarker in the pathophysiology of this metabolic syndrome. The gene discussed is SESN2; the disease is polycystic ovary syndrome.